What Veradermics’ latest oral minoxidil data reveal about long-term hair growth
Veradermics reports sustained VDPHL01 hair growth at 12 months. See what the results mean for safety, FDA review and commercial potential.
Pharma & Biotech
Pharma & Biotech
What the Veradermics Phase 3 results mean for oral minoxidil treatment
Veradermics reports strong Phase 3 VDPHL01 hair growth results in 536 men. Efficacy is encouraging, but safety and FDA review remain crucial.
Pharma & Biotech
Can VDPHL01 carry its male-trial momentum into women? Veradermics is about to show the data
See why Veradermics’ Study 207 female data could shape VDPHL01 dose selection, safety expectations and its Phase 3 clinical strategy.
Pharma & Biotech
Why the Veradermics hair loss trial is bigger than another aesthetics readout
Hair loss drugs are old, demand is huge, and Veradermics now faces the data test that could reset oral minoxidil’s commercial future.
Pharma & Biotech
Will Veradermics’ non-hormonal oral pill become the first FDA-approved hair loss therapy in decades?
Veradermics just completed pivotal trial enrollment for VDPHL01, its oral minoxidil for hair loss. Will it reshape dermatology? See what’s next.